Traditional Chinese Medicine Combined with Peginterferon α-2b in Chronic Hepatitis B: A Real-world Cohort Study

Abstract

Background and objectives: Peginterferon- α treatment exhibits low rates of the serological conversion rate of hepatitis B e antigen (HBeAg) and the negative conversion rate of hepatitis B virus (HBV) DNA, with significant myelosuppression leading to treatment discontinuation in some patients. Traditional Chinese medicine (TCM) may ameliorate liver inflammation and modulate immune responses. This study aims to investigate the efficacy of combining TCM with pegylated-interferon (PEG-IFN) α-2b and its impact on myelosuppression adverse effects.

Methods: This study included 117 HBeAg-positive chronic hepatitis B (CHB) patients who started initial antiviral therapy at Xiamen Hospital of TCM between June 2018 and January 2023. According to the treatment regimen, patients were divided into the observation group (n = 56, receiving PEG-IFN α-2b combined with Licorice 15 g, Angelica sinensis 20 g, Poria 20 g, Paeonia lactiflora 20 g, Rhizoma Atractylodis Macrocephalae 20 g, Radix Bupleurum Chinense 20 g, Mentha piperita 3 g, Ginger three slices for more than six months) and the control group (n = 61, receiving PEG-IFN α-2b alone). This study retrospectively analyzed etiological indicators, liver biochemical indicators, and blood routine tests before and after treatment.

Results: After 24 and 48 weeks of treatment, the observation group demonstrated significantly superior outcomes to the control group in quantitative reduction of hepatitis B surface antigen, the serological conversion rate of HBeAg, and the reduction in HBV DNA quantification (P < 0.05). By week 48, the HBV DNA negative conversion rate in the observation group (46.67%) was significantly higher than that in the control group (26.67%) (P < 0.05). Regarding safety, the incidence of myelosuppression in the observation group was significantly lower than that in the control group at both 24 and 48 weeks of treatment (P < 0.05)

Conclusions: Real- world findings demonstrate that adjunctive TCM significantly enhances the antiviral efficacy of peginterferon α-2b in HBeAg-positive CHB patients while concurrently mitigating treatment-limiting myelosuppression. This combination strategy may represent a clinically valuable approach to optimizing interferon-based therapy for CHB.

Keywords

Chronic hepatitis B / CHB / Real-world research / Traditional Chinese medicine / TCM / Interferon

References

[1] Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ 2019; 97(3):230-238. doi:10.2471/BLT.18.219469, PMID:30992636.

[2] Yang L, Yang X, Kong X, Cao Z, Zhang Y, Hu Y, et al. Covariation Analysis of Serumal and Urinary Metabolites Suggests Aberrant Glycine and Fatty Acid Metabolism in Chronic Hepatitis B. PLoS One 2016; 11(5):e0156166. doi:10.1371/journal.pone.0156166, PMID:27228119.

[3] Huang Z.Real-world Study On The Improvement of Liverhistopathology In Chronic Hepatitis B by Combining Traditional Chinese Medicine Decoction with Pegylated Interferon α-2b [Dissertation]. Fuzhou: Fujian University of Traditional Chinese Medicine; 2024. doi:10.27021/d.cnki.gfjzc.2024.000198.

[4] Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Zhonghua Gan Zang Bing Za Zhi 2019;27(12):938-961. doi:10.3760/cma.j.issn.1007-3418.2019.12.007, PMID:31941257.

[5] Tian Y, Kuo CF, Akbari O, Ou JH. Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission. Immunity 2016; 44(5):1204-1214. doi:10.1016/j.immuni.2016.04.008, PMID:27156385.

[6] Guo Z, He W, Pei J. Effect of pegylated interferon α-2a injection combined with Tenof ovir diaxidate in the treatment of e antigen-positive chronic hepatitis B. Chinese Remedies & Clinics 2019; 19(22):3944-3946. doi:10.11655/zgywylc2019.22.053.

[7] Hepatobiliary Specialized Committee of China Associationof Chinese Medicine,Liver Diseases Specialized Committee of China Medical Association of Minorities. Guidelines for TCM Diagnosis and Treatment of Chronic Hepatitis B (2018 version). Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2019; 29(1):97-102. doi:10.3969/j.issn.1005-0264.2019.01.032.

[8] Lin J, Cheng S, Huang C. Application of interferon in the treatment of chronic hepatitis B. J Mod Med Health 2018; 34(24):3745-3748. doi:10.3969/j.issn.1009-5519.2018.24.001.

[9] Kim V, Abreu RM, Nakagawa DM, Baldassare RM, Carrilho FJ, Ono SK. Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis. J Viral Hepat 2016; 23(3):154-169. doi:10.1111/ jvh.12418, PMID:25967226.

[10] Maolaaisha A, Manapu B, Gulijiaziyila, Bali R. Effect of different drug regimens on HBeAg-positive chronic hepatitis B and its influence on serum IFN-γ and IL-10. China Medical Herald 2017; 14(5):137-140.

[11] Wu X.A Real-world Study of Traditional Chinese Medicine Decoction Combined With Peginterferon α-2b in the Treatment of Chronic Viral Hepatitis B [Dissertation]. Fuzhou: Fujian University of Traditional Chinese Medicine; 2023. doi:10.27021/d.cnki.gfjzc.2023.000196.

[12] Guo Y, Zhang J. Influencing factors for the functional cure of chronic hepatitis B and related mechanism. J Clin Hepatol 2019; 38(8):1721-1725. doi:10.3969/j.issn.1001-5256.2022.08.004.

[13] Wang ZL.Effects of Soothing Liver and Reinforcing Spleen Serum on JAK2,STAT3mRNA and HBsAg in the HepG2.2.15 Cells [Dissertation]. Fuzhou: Fujian University of Traditional Chinese Medicine; 2017.

[14] Guo Y, Hu Y, Jiang Q, Huang M, Liu A, Zhang J. Performance verification and clinical application of quantitative detection of hepatitis Bviruse antigen. Journal of Microbes and Infections 2021; 16(6):391-397. doi:10.3969/j.issn.1673-6184.2021.06.004.

[15] Zheng XT.Clinical observation of acupoint application of Chinese medicine combined with pegylated interferon α-2b in the treatment of chronic hepatitis B with liver-Qi and spleen-deficiency syndrome [Dissertation]. Fuzhou: Fujian University of Traditional Chinese Medicine; 2021.

[16] Qi C, Wang L, Li W, Zhou J, Chen J, Zhao H, et al. Clinical efficacy and mechanism of self-prepared Jiedu Sanyu Ruanjian prescription combined with Entecavir in the treatment of damp-heat moderateobstructive CHB patients. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2022; 32(10):870-874. doi:10.3969/j.issn.1005-0264.2022.010.002.

[17] Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man RA, Schalm SW, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut 2005; 54(11):1604-1609. doi:10.1136/ gut.2004.062208, PMID:15923670.

[18] Tang Y, Qin B. Research progress on predictors for efficacy of pegylated interferon in the treatment of chronic hepatitis B. Chin J Infect Chemother 2025; 25(2):218-223. doi:10.16718/j.1009-7708.2025.02.017.

[19] Cao S, Wang C, Bai J, Sun S, Liu G. A review on treating chronic hepatitis B in the integrative medicine. Clinical Journal of Chinese Medicine 2020; 12(4):142-145. doi:10.3969/j.issn.1674-7860.2020.04.054.

[20] Zhang QH, Wu CF, Duan L, Yang JY. Protective effects of total saponins from stem and leaf of Panax ginseng against cyclophosphamideinduced genotoxicity and apoptosis in mouse bone marrow cells and peripheral lymphocyte cells. Food Chem Toxicol 2008; 46(1):293-302. doi:10.1016/j.fct.2007.08.025, PMID:17904265.